huIL5 Mouse
製品名
huIL5 Mouse
製品ID
C001813
系統名
C57BL/6NCya-Il5tm1(hIL5)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huIL5 Mouse（カタログ番号C001813）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
EDF, TRF, IL-5
NCBI ID
染色体
Chr 5
MGI ID
さらに
系統詳細
Interleukin-5 (IL-5) is a cytokine secreted by Th2 CD4+ T cells, mast cells, and type 2 innate lymphoid cells (ILC2s). It plays a pivotal role in regulating the proliferation, differentiation, activation, and survival of eosinophils [1]. The IL5 gene is located within the 5q31 region of human chromosome 5, clustered alongside other Th2 cytokine genes such as IL4 and IL13, and is co-regulated by transcription factors including GATA3 [2]. By binding to the IL-5 receptor alpha chain (IL-5Rα), IL-5 activates signaling pathways like JAK2-STAT5, thereby modulating eosinophil-associated immune responses [1-2]. Aberrant IL-5 expression is closely linked to various eosinophil-related disorders, including asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), hypereosinophilic syndrome, and allergic rhinitis, making the IL-5/IL-5Rα axis a prominent therapeutic target. Consequently, several antibody drugs targeting IL-5 or IL-5Rα, such as Mepolizumab and Benralizumab, have been approved or are currently under clinical investigation [3-4].
The huIL5 mouse is a humanized model generated by replacing the mouse Il5 gene sequence (from the start codon to the stop codon) with the corresponding human IL5 sequence via in situ substitution. This model is highly valuable for studying eosinophilic diseases (e.g., asthma, CRSwNP, and hypereosinophilic syndrome), allergic inflammatory immune regulation, and Th2 immune responses. Furthermore, it serves as a robust platform for the development of IL-5-targeted therapeutics.
参考文献
Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(8):463-485.
Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40(4):563-575.
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM). Lancet. 2012;380(9842):651-659.
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma. Lancet. 2016;388(10056):2128-2141.
系統作製戦略
The sequences from the start codon to the stop codon of the endogenous mouse Il5 gene were replaced with the sequences from the start codon to the stop codon of the human IL5 gene.
Figure 1. Gene editing strategy for huIL5 mice.
適用分野
Research on asthma and eosinophilic airway diseases;
Studies on chronic rhinosinusitis with nasal polyps (CRSwNP) and hypereosinophilic syndrome;
Investigation of allergic rhinitis and atopic dermatitis;
Mechanistic studies of allergic inflammation;
Preclinical evaluation of IL-5-targeted therapeutics;
In vivo validation of immunotherapies;
Cytokine signaling pathway research.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。